Fluticasone furoate clinical trials
Also written GW685698X and Veramyst.
A product of Fluticasone; its studies count on that page too.
Related medicines add 2 studies
Counted the way a researcher would: Fluticasone furoate with its salts, dosage forms, brands and biosimilars. Looking for a trial to join? Including related medicines shows more you could take part in.
This browser remembers your choice.
How each study uses fluticasone furoate is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the fluticasone furoate studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 27 Apr 2007 · FLONASE SENSIMIST ALLERGY RELIEF · NDA 022051 (FDA, Drugs@FDA)
- European Union
- 11 Jan 2008 · Avamys · EMEA/H/C/000770 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Name
Development codes
- GW685698X
- 16
Studies by the year they started
104 studies that test it; most in 2005 (14)
| Year | Studies |
|---|---|
| 2003 | 1 |
| 2004 | 1 |
| 2005 | 14 |
| 2006 | 4 |
| 2007 | 9 |
| 2008 | 7 |
| 2009 | 5 |
| 2010 | 9 |
| 2011 | 9 |
| 2012 | 6 |
| 2013 | 2 |
| 2014 | 5 |
| 2015 | 4 |
| 2016 | 3 |
| 2017 | 3 |
| 2018 | 7 |
| 2019 | 3 |
| 2021 | 1 |
| 2022 | 3 |
| 2023 | 5 |
| 2024 | 1 |
| 2025 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 84 · Other 21
GlaxoSmithKline (82) · University of Chicago (5) · University of Saskatchewan (2) · Morten Hostrup, PhD (2) · Dr. Grace Parraga (1) · Thammasat University (1) · Rambam Health Care Campus (1) · Sandoz (1)
Often tested with
Tested in the same studies.
Vilanterol (33) · GSK573719 (15) · Vilanterol trifenatate (3) · Umeclidinium bromide (2) · Tiotropium (2) · Batefenterol (2) · Fexofenadine (2) · Olopatadine (2)
Related medicines
As reviewed, each with the page that says it.
- A salt or form of Fluticasone
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 2, 1 in phase 3
Studies that test fluticasone furoate, phase 3 first.
- Jan 2027A Study to Compare the Efficacy, Safety and Tolerability of FF/UMEC/VI With FF/VI in 12-17-year-olds With AsthmaPhase 3 · GlaxoSmithKline
- Sep 2027129-Xe MRI Study of Single Triple Therapy Inhaler Effects in COPD Patients With Moderate-severe Dyspnea and/or Poor Health Status With High or Low Risk of ExacerbationPhase 4 · Western University, Canada
Studies
Open first, then newest update. How each study uses fluticasone furoate is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 105
- 129-Xe MRI Study of Single Triple Therapy Inhaler Effects in COPD Patients With Moderate-severe Dyspnea and/or Poor Health Status With High or Low Risk of ExacerbationRecruitingPhase 4Western University, CanadaNCT07192016Written as fluticasone furoate(FF)/umeclidinium (UMEC)/vilanterol(VI) (100/62.5/25) mcg
- U-LABA/ICS Effects on Exercise Performance, VilanterolRecruitingNot applicableMorten Hostrup, PhDNCT06066606Written as Vilanterol and Fluticasone Furoate (low dose)
- Role of Lung Function for Exercise Capacity in Well-trained IndividualsRecruitingNot applicableMorten Hostrup, PhDNCT06077019Written as Vilanterol and Fluticasone Furoate
- Effect of the Inhaled Triple Therapies Over the Small Airway in Biomass ExposureRecruitingPhase 4National Institute of Respiratory Diseases, MexicoNCT06571942Written as Fluthicasone / Vilanterol / Umeclidinium (100/25/62.5 mcg)
- A Study to Compare the Efficacy, Safety and Tolerability of FF/UMEC/VI With FF/VI in 12-17-year-olds With AsthmaActive, not recruitingPhase 3GlaxoSmithKlineNCT05757102Written as FF/UMEC/VI
- Pragmatic Open - Label Randomized Clinical Trial of FF/UMEC/VI vs Non-ellipta Usual Care ICS-LABA for Adult Participants With Uncontrolled AsthmaActive, not recruitingPhase 4GlaxoSmithKlineNCT06372496Written as Fluticasone furoate/umeclidinium bromide/vilanterol trifenatate
- Comparative Effects of Triple Inhaled Therapy With Budesonide/Glycopyrronium/Formoterol Versus Fluticasone Furoate/Umeclidinium/Vilanterol on Small Airway Disease in COPD Patients: A Randomized Crossover StudyCompletedPhase 4Thammasat UniversityNCT06905483Written as Fluticasone Furoate/Umeclidinium/Vilanterol (FUV)
- To Evaluate Real-World Effectiveness of Fluticasone Furoate/Umeclidinium Bromide/Vilanterol (FF/UMEC/VI) in a Single Inhaler (Trelegy Ellipta) in Participants With Symptomatic COPDCompletedPhase 4GlaxoSmithKlineNCT05535972Written as FF/UMEC/VI
- Evaluation of Triple Therapy Using Magnetic Resonance Imaging in AsthmaActive, not recruitingPhase 3Dr. Grace ParragaNCT04651777Written as FF/UMEC/VI
- Efficacy and Safety of Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) in Chinese Participants With Inadequately Controlled AsthmaCompletedPhase 3GlaxoSmithKlineNCT04937387Written as FF/VI
- A Study to Evaluate the Safety and Efficacy of Fluticasone Furoate (FF)/Umeclidinium(UMEC)/Vilanterol (VI) in Participants With Chronic Obstructive Pulmonary Disease (COPD)CompletedPhase 4GlaxoSmithKlineNCT04923347Written as FF/UMEC/VI
- Effects of a Orally Inhaled Fluticasone Furoate on Growth Velocity in Prepubertal, Paediatric Subjects With Asthma Over a YearCompletedPhase 4GlaxoSmithKlineNCT02889809Written as Fluticasone furoate
- Medical vs Surgical Treatment in OSA Among ChildrenStatus unknownPhase 4Assaf-Harofeh Medical CenterNCT05651750Written as Fluticasone Furoate
- A Comparative Study Between Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Single Inhaler Triple Therapy Versus Tiotropium Monotherapy in Subjects With Chronic Obstructive Pulmonary Disease (COPD)CompletedPhase 4GlaxoSmithKlineNCT03474081Written as FF/UMEC/VI
- Effect of Fluticasone Furoate/Vilanterol on EIA in AdolescentsCompletedPhase 4Rambam Health Care CampusNCT04750603Written as Fluticasone furoate (FF)/Vilanterol (VI)
- A Study Comparing Two Fluticasone Furoate Nasal Sprays in the Relief of the Signs and Symptoms of Seasonal Allergic RhinitisCompletedPhase 3SandozNCT01279057Written as Fluticasone furoate 27.5 mcg/actuation nasal spray (Lek Pharmaceuticals)
- Urine Concentrations of Vilanterol After Inhaled Administration of Vilanterol/Fluticasone FuroateCompletedPhase 2Bispebjerg HospitalNCT03739294Written as Fluticasone Furoate/ Vilanterol Trifenatate
- A Randomized Study, Comparing Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC /VI) Single Inhaler Triple Therapy, Versus Multiple Inhaler Therapy (Budesonide/Formoterol Plus Tiotropium) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)CompletedPhase 4GlaxoSmithKlineNCT03478696Written as FF/UMEC/VI
- A Randomized Study, Comparing Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Single Inhaler Triple Therapy, Versus Multiple Inhaler Therapy (Budesonide/Formoterol Plus Tiotropium) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)CompletedPhase 4GlaxoSmithKlineNCT03478683Written as FF/UMEC/VI
- INTREPID: Investigation of TRELEGY Effectiveness: Usual Practice DesignCompletedPhase 4GlaxoSmithKlineNCT03467425Written as FF/UMEC/VI
See all 105 studies that test fluticasone furoate →
Given beside what is tested · 21 — fluticasone furoate is usual care or a partner of the new treatment
- Role of Montelukast in the Management of Chronic Rhinosinusitis With Nasal Polyps.Status unknownPhase 1/2Assiut UniversityNCT05143502Written as Fluticasone Furoate
- Phase IIb Study of Umeclidinium (UMEC) Bromide Versus Placebo in Subjects With AsthmaCompletedPhase 2GlaxoSmithKlineNCT03012061Written as Fluticasone Furoate
- Comparative Study of Fluticasone Furoate(FF)/Umeclidinium Bromide (UMEC)/ Vilanterol (VI) Closed Therapy Versus FF/VI Plus UMEC Open Therapy in Subjects With Chronic Obstructive Pulmonary Disease (COPD)CompletedPhase 3GlaxoSmithKlineNCT02729051Written as FF/UMEC/VI
- An Effectiveness Study Comparing Fluticasone Furoate (FF, GW685698)/Vilanterol (VI, GW642444) With Standard Treatment in AsthmaCompletedPhase 3GlaxoSmithKlineNCT01706198Written as fluticasone furoate + vilanterol
- Effect of Health Promotion on Allergic Rhinitis by Infrared-C Ray IrradiationCompletedNot applicableNanhua UniversityNCT03673384Written as Fluticasone Furoate
- Fluticasone Furoate/GW642444 Inhalation Powder Long-Term Safety StudyCompletedPhase 3GlaxoSmithKlineNCT01018186Written as Fluticasone Furoate/GW642444
- Study to Compare the Addition of Umeclidinium Bromide (UMEC) to Fluticasone Furoate (FF)/Vilanterol (VI), With Placebo Plus FF/VI in Subjects With Chronic Obstructive Pulmonary Disease (COPD)CompletedPhase 3GlaxoSmithKlineNCT01957163Written as FF
- A Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetic (PK), and Pharmacodynamic (PD) Profiles of 3 Doses of Fluticasone Furoate (FF)/GW642444 Inhalation Powder at the End of a 28-day Treatment Period in Subjects With Chronic Obstructive Pulmonary Disease (COPD) Compared to PlaceboCompletedPhase 3GlaxoSmithKlineNCT01072149Written as Fluticasone Furoate (FF)/GW642444 Inhalation Powder
- A 24-week Arterial Stiffness Study With Fluticasone Furoate/Vilanterol in COPDCompletedPhase 3GlaxoSmithKlineNCT01336608Written as Fluticasone Furoate/Vilanterol
- Evaluation of Umeclidinium Bromide in Combination With Fluticasone Furoate in COPD Subjects With an Asthmatic ComponentCompletedPhase 2GlaxoSmithKlineNCT02164539Written as FF
- Comparing Two Respiratory Drugs When Used In Combination And Separately From A Novel Inhaler Device In Healthy SubjectsCompletedPhase 1GlaxoSmithKlineNCT00538057Written as GW685698X & GW642444M
- Relovair PD PK in Chinese Healthy SubjectsCompletedPhase 1GlaxoSmithKlineNCT01711463Written as Fluticasone Furoate/Vilanterol
- Corrected QT (QTc) Study With Flucticasone Furoate and GW642444CompletedPhase 1GlaxoSmithKlineNCT01209026Written as Fluticasone furoate (200 mcg)/GW642444 (25mcg) combination
- A Randomised Effectiveness Study Comparing Fluticasone Furoate (FF, GW685698)/Vilanterol (VI, GW642444) With Standard Treatment in Chronic Obstructive Pulmonary Disease (COPD)CompletedPhase 3GlaxoSmithKlineNCT01551758Written as FF/VI
- Study to Compare the Addition of Umeclidinium Bromide (UMEC) to Fluticasone Furoate (FF)/Vilanterol (VI), With Placebo Plus FF/VI in Subjects With Chronic Obstructive Pulmonary Disease (COPD) -Study 2CompletedPhase 3GlaxoSmithKlineNCT02119286Written as FF
- Safety Study of the Effects of Inhaled Fluticasone Furoate/GW642444 on the Hypothalamic-Pituitary-Adrenal (HPA) AxisCompletedPhase 3GlaxoSmithKlineNCT01086410Written as Fluticasone Furoate/GW642444 Inhalation Powder
- A Long-term Safety Study of Fluticasone Furoate (FF)/GW642444 and FF in Japanese Subjects With AsthmaCompletedPhase 3GlaxoSmithKlineNCT01244984Written as Fluticasone Furoate/GW642444 Inhalation Powder
- Inhaled Fluticasone Furoate/Vilanterol Safety and Tolerability, PK and PD StudyCompletedPhase 2GlaxoSmithKlineNCT01453023Written as Fluticasone Furoate
- A 24-week Study of Fluticasone Furoate/Vilanterol Inhalation Powder in Subjects of Asian Ancestry With COPDCompletedPhase 3GlaxoSmithKlineNCT01376245Written as fluticasone furoate/vilanterol
- A Proof of Concept Study to Assess Effect of Fluticasone Furoate (FF)/Levocabastine Fixed Dose Combination (FDC) Compared With Levocabastine and FF Alone in Subjects With Allergic Rhinitis (AR)CompletedPhase 2GlaxoSmithKlineNCT01957202Written as FF
Showing 20 of 21.
As the comparator · 3 — what is tested is compared with fluticasone furoate
- Comparative Study of Fluticasone Furoate(FF)/Umeclidinium Bromide (UMEC)/ Vilanterol (VI) Closed Therapy Versus FF/VI Plus UMEC Open Therapy in Subjects With Chronic Obstructive Pulmonary Disease (COPD)CompletedPhase 3GlaxoSmithKlineNCT02729051Written as FF/UMEC/VI
- Evaluate the Safety, Efficacy and Dose Response of GSK573719 in Combination With Fluticasone Furoate in Subjects With AsthmaCompletedPhase 2GlaxoSmithKlineNCT01573624Written as FF
- Inhaled Fluticasone Furoate/Vilanterol Safety and Tolerability, PK and PD StudyCompletedPhase 2GlaxoSmithKlineNCT01453023Written as Fluticasone Furoate
Codes
What other systems call fluticasone furoate · ClinicalTrials.gg INT005163
- MeSH (NLM) C523187fluticasone furoateOne source NLM
- UNII (FDA) JS86977WNVFLUTICASONE FUROATEConfirmed FDA, NLM, Wikidata
- RxNorm 705022Confirmed FDA, Wikidata
- Wikidata Q2166700fluticasone furoateConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C77003Fluticasone FuroateOne source FDA
- DrugBank DB08906One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C523187 | fluticasone furoate | One source NLM |
| UNII (FDA) | JS86977WNV | FLUTICASONE FUROATE | Confirmed FDA, NLM, Wikidata |
| RxNorm | 705022 | — | Confirmed FDA, Wikidata |
| Wikidata | Q2166700 | fluticasone furoate | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C77003 | Fluticasone Furoate | One source FDA |
| DrugBank | DB08906 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.